We provide early stage capital to disruptive, deep technology companies and life sciences businesses in therapeutics, medtech/diagnostics, digital health and genomics/proteomics

Andrew Williamson

Managing Partner

Andrew Williamson is the Managing Partner of CIC and focuses on technology investments.

Andrew’s background combines R&D, start-up formation and technology investing. Before joining CIC he spent ten years in venture investing at Physic Ventures in San Francisco and True North Venture Partners in Chicago. Before moving into Venture Capital, Andrew led a research group applying High Performance Computing to materials science at Lawrence Livermore National Laboratory.
Andrew has an MA and PhD in Physics from the University of Cambridge and an MBA from the Haas School of Business at the University of California, Berkeley.
Andrew manages CIC's investments in Audio Analytic, AudioTelligence, Origami Energy, PragmatIC, Secondmind, Swim and Riverlane.


Michael Anstey


Dr Michael Anstey is a Partner specialising in life science investments.

Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational businesses across North America, Europe, India, and Japan.
Michael was also co-founder of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked at Oxford Capital Partners, where he focused on investing in early stage life science businesses.
Michael earned his DPhil in Zoology in the field of neurobiology from the University of Oxford.
Michael manages CIC's investments in Bicycle Therapeutics (NASDAQ: BCYC), Congenica, Immutrin, PredictImmune, PolyProx Therapeutics, Sense Bio, Start Codon and Storm Therapeutics.


Carol Cheung


Carol is a Principal focusing on a range of technology investments.

Prior to joining CIC she worked in a variety of roles at several UK-based early stage tech companies, most recently as Commercial Director of Speechmatics, a Cambridge-based speech recognition start-up. She has a background in financial analysis gained from working in both the UK and Canada. She holds a B. Comm from the University of Toronto, gained an MBA from the University of Cambridge’s Judge Business School and is a CFA charterholder.
Carol manages CIC's investment in Cytora and Geospock.


Anne Horgan


Anne Horgan is a Partner focusing on biotech and biopharma investments.

Prior to joining CIC Anne was a Partner at Advent France Biotechnology, a Paris-based venture capital firm specialising in Life Sciences seed investments, and Senior Associate at Sofinnova Partners.
Anne brings 17 years’ experience, acquired as Business Development Executive at Cancer Research Technology and Senior Medicinal Chemist at Cambridge Biotechnology (now part of Benevolent AI). Anne’s experience includes equity financing (seed and series A), technology transfer and scouting, business development and biotech R&D.
Anne carried out postdoctoral research at Yale University after her PhD in synthetic organic chemistry from the University of Bristol. She holds a diplôme d’ingénieur (Chemistry) from the Institut National des Sciences Appliquées de Rouen, authored several peer-reviewed papers and is an inventor on eight patent families.

Ian Jauncey

Operating Partner

Ian is a Board observer for CIC’s investments in a number of our portfolio companies.

Ian is a technology and life sciences investor and entrepreneur. He shares his time between managing his private investment portfolio and assisting CIC companies through critical growth stages.
Following university, Ian was the lead in the world beating team that invented the first optical fibre amplifier, a key enabler for the internet. He has worked in analysis and consultancy, eventually heading up a business division for Siemens AG. Subsequently he initiated tech businesses, acquired others and grew them internationally, leading to multiple exits.
Ian has a BA in Natural Sciences from Oxford, a PhD from Southampton University and is a Chartered Director.


Ian Lane


Ian Lane is a Partner and focuses on technology investments.

Before joining CIC Ian was a Director at Unilever Ventures in London, where he led all B2B/Technology investments. Over 11 years he was responsible for numerous transactions across Europe and North America, including investments into Olapic (acquired by Monotype Inc), Mirakl, Aera Technology, Skupos, WeGift, Celtra, CreatorIQ, Mirriad (Listed on AIM) and Blis Global. Prior to Unilever Ventures, Ian worked at L.E.K. Consulting in London and Australia, working on strategy consulting and private equity due-diligence projects.

Ian has PhD in Physical Chemistry from the University of Cambridge and Msci in Chemistry from Bristol University.

Ian manages CIC's investment in AudioTelligence and Seldon.


Rob Sprawson

Partner and CFO

Rob has more than 25 years of professional and commercial experience providing strategic, financial and corporate finance advice to boards and shareholders, especially in the life science, technology and technology consulting industries.
His previous roles have included CFO of Altacor, an ophthalmic specialty pharmaceutical company, CFO of Warwick Ventures, the Technology Transfer Office of Warwick University, CFO of an AIM listed drug development company and Senior Manager, Corporate Finance at PwC. Rob was also a consultant to Lumora, a molecular diagnostics company spun-out from the University of Cambridge.  Rob manages CIC's investment in Imagen. 

He is a Fellow of the Institute of Chartered Accountants in England and Wales.


Robert Tansley


After seven years working in hospital medicine, Robert worked in development and regulatory roles at Sanofi, the MHRA and Roche. Robert then spent a decade at early stage biotech companies including Arakis (sold to Sosei Inc), founder and CEO at Treague, founding CEO of the University of Copenhagen spin -out Avilex Pharma and part of the founding management team of KalVista (Nasdaq: KALV). Robert qualified in medicine from UCL. He is a member of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine and has an MBA from London Business School and an M.Phil in Biostatistics from the University of Cambridge. Robert manages CIC's investments in Abcodia, Carrick Therapeutics, CMR Surgical, Exvastat, Gyroscope, Inivata, Microbiotica, Morphogen-IX and PetMedix.


Chris Tapper


Chris is an Associate specialising in life science investments.

Prior to joining CIC Chris worked at C4X Discovery, an AIM-listed drug discovery biotechnology company, as part of the Corporate Strategy and Development team, where he focused on identifying and sourcing opportunities for in-licensing, collaboration and internal development. Chris also brings a background in strategy consulting and due diligence support, working in L.E.K. Consulting’s Life Sciences practice across the UK and US.
Chris holds an MA in Medical Sciences from the University of Cambridge.

Michelle Lamprecht

Head of Marketing

Michelle Lamprecht is Head of Marketing. She has 20 years experience of international leadership in strategic marketing across a range of public and privately owned organisations. Prior to CIC Michelle’s previous roles were Group VP Marketing for Sepura and VP Marketing for The Vitec Group Production Solutions division.
Michelle has been a board member for Byte Night (Action for Children), a trustee for Citizen’s Advice and is currently a mentor for the Aspire Foundation.
Michelle has a BSc (Hons) in chemistry from the University of Hertfordshire and a post graduate diploma in marketing from the Chartered Institute of Marketing.

Nick Richards

General Counsel and Company Secretary

Nick has over 15 years’ experience advising institutional, corporate and individual investors and the companies they invest into, especially in the technology and life sciences sectors.
Nick qualified into the private equity team of a Magic Circle law firm and has been seconded to the legal department of Goldman Sachs. Prior to joining CIC, Nick was a senior associate at an international law firm.
Nick attended the College of Law and BPP Law School in London and holds an MA in Modern Languages from the University of Oxford. He is a solicitor admitted to practise in England and Wales.

Helen Slack

Executive Assistant

Helen is Executive Assistant to the Life Science Partners, Robert Tansley and Michael Anstey.

Prior to CIC, Helen worked for the NHS and also in Private Healthcare. She has experience of working in management, administrative and clinical roles. Helen has lived in and around Cambridge for most of her life.

Sylwia Szulc

Finance Manager

Sylwia joined CIC as the Finance Manager in 2019.

Sylwia has more than nine years’ accountancy experience, and most recently worked in a busy accountancy practice in Cambridge. She has a BSc in Marketing and Management and an MSc in Marketing from the University of Nicolas Copernicus in Poland. Having grown up in Poland, Sylwia has lived and worked in Cambridge for the last fifteen years. Sylwia is a Member of the Association of Chartered Certified Accountants.

Ellie Terry

Personal Assistant and Office Manager

Ellie is Assistant to the senior team and manages the office.

She has extensive knowledge of Cambridge, having spent over 3 years at Cambridge Enterprise, the University’s commercialisation arm, providing administrative support to the Consultancy Team. Prior to that Ellie worked at Xtravirt Ltd and Savills plc.

Victoria Woodward

Head of Business Support

Victoria is Head of Business Support at CIC. As well as managing the administrative team, Victoria coordinates CIC's strategic initiatives and supports the Managing Partner, CFO and Chairman.

Victoria specialises in project management and business development and has almost twenty years’ experience. Prior to CIC, Victoria most recently worked for PA Consulting, OC&C Strategy Consultants and Tyndall AM, which is now Nikko Asset Management.

  • Abcodia


    CEO, Julie Barnes

    CIC oversight:  Robert Tansley

    Developing Novel Tests for the Early Detection of Cancer

  • Audio Analytic

    Audio Analytic

    CEO & Founder, Chris Mitchell

    CIC oversight:  Andrew Williamson

    We've empowered machines with the sense of hearing

  • AudioTelligence


    CEO, Ken Roberts

    CIC oversight:  Andrew Williamson

    Leading the world in blind audio signal separation from multi-microphone audio

  • Bicycle Therapeutics

    Bicycle Therapeutics

    CEO, Kevin Lee

    CIC oversight:  Michael Anstey

    We didn’t wait for the next advance against cancer. We created it.

  • Carrick Therapeutics

    Carrick Therapeutics

    CEO, Timothy Pearson

    CIC oversight:  Robert Tansley

    Clinical stage oncology drug development company

  • CMR Surgical

    CMR Surgical

    CEO, Per Vegard Nerseth

    CIC oversight:  Robert Tansley

    Transforming surgery. For good.

  • Congenica


    CEO, David Atkins

    CIC oversight:  Michael Anstey

    Revolutionising the way genetic diseases are characterized and diagnosed

  • Cytora


    CEO, Richard Hartley

    CIC oversight:  Carol Cheung

    Powering the future of commercial insurance

  • Exvastat


    Director, David Cavella

    CIC oversight:  Robert Tansley

    Developing a novel treatment for acute respiratory distress syndrome (ARDS)

  • Fluidic Analytics

    Fluidic Analytics

    CEO, Andrew Lynn

    CIC oversight:  Robert Tansley

    Changing the way proteins are characterised

  • Geospock


    Founder, CEO and CTO, Steve Marsh

    CIC oversight:  Carol Cheung

    Make decisions that matter, be part of the future of location analytics

  • Gyroscope Therapeutics

    Gyroscope Therapeutics

    CEO, Khurem Farooq

    CIC oversight:  Robert Tansley

    Developing genetically-defined therapies for the treatment of eye diseases

  • Imagen


    CEO, Charlie Horell

    CIC oversight:  Rob Sprawson

    Unleash your videos' potential

  • Inivata


    CEO, Clive Morris

    CIC oversight:  Robert Tansley

    A leader in liquid biopsy

  • Microbiotica


    Co-founder and CEO, Mike Romanos

    CIC oversight:  Robert Tansley

    Transforming personalised medicine with leading microbiome science

  • Morphogen-IX


    CSO, Nick Morrell

    CIC oversight:  Robert Tansley

    Developing transformative drugs for the treatment of pulmonary arterial hypertension

  • Origami Energy

    Origami Energy

    CEO, Peter Bance

    CIC oversight:  Andrew Williamson

    Technology to help you balance supply and demand

  • PetMedix


    CEO, Thomas Weaver

    CIC oversight:  Robert Tansley

    Bringing antibody innovation to animal health

  • Polyprox Therapeutics

    Polyprox Therapeutics

    CSO, Laura Itzhaki

    CIC oversight:  Michael Anstey

    Developing Polyproxin™ drug candidates that target and remove disease-causing proteins

  • PragmatIC


    CEO, Scott White

    CIC oversight:  Andrew Williamson , Ian Jauncey

    Create more

  • Predictimmune


    Acting CEO & Chairman, Andy Sandham

    CIC oversight:  Michael Anstey

    Enabling better treatment and outcomes for patients with chronic immune-mediated diseases

  • Pretzel Therapeutics

    Pretzel Therapeutics

    Co-Founders, Claes Gustafsson, Michal Minczuk, Nils-Göran Larsson

    CIC oversight:  Robert Tansley

    Welcome to a new era in mitochondrial therapeutics

  • Riverlane


    CEO & Founder, Steve Brierley

    CIC oversight:  Andrew Williamson

    Pioneering quantum software

  • Secondmind


    CEO, Gary Brotman

    CIC oversight:  Andrew Williamson

    People powered by AI make better decisions

  • Seldon


    CEO & Founder, Alex Housley

    CIC oversight:  Ian Lane

    Machine learning deployment for enterprise

  • Sense Biodetection

    Sense Biodetection

    CEO, Timothy Still

    CIC oversight:  Michael Anstey

    Transforming diagnostics

  • Storm Therapeutics

    Storm Therapeutics

    CEO, Keith Blundy

    CIC oversight:  Michael Anstey

    Harnessing the power of RNA epigenetics

  • SWIM


    CEO, Ramana Jonnala

    CIC oversight:  Andrew Williamson

    Transform streaming data into real-time insights

  • Undo


    CEO, Barry Morris

    CIC oversight:  Ian Jauncey

    Reduce software defect resolution time

  • Z Factor

    Z Factor

    Founder and Director, James Huntington

    CIC oversight:  Robert Tansley

    Developing a novel therapeutic agent for alpha-1-antitrypsin deficiency